- Sun Pharma reported a net income of 22.8 billion rupees for the first quarter, which is a 20% decline compared to the previous year and below the estimate of 29.61 billion rupees.
- The company recorded a revenue of 138.5 billion rupees, showing a 9.5% increase year-over-year and surpassing the estimate of 136.99 billion rupees.
- Sales in India reached 47.21 billion rupees, beating the estimate of 46.12 billion rupees.
- US revenue was $473 million, which fell short of the estimated $482.9 million.
- Sales of active pharmaceutical ingredients stood at 5.40 billion rupees.
- Research and Development (R&D) expenses totaled 9.03 billion rupees during the quarter.
- Analyst ratings on Sun Pharma comprised of 36 buy recommendations, 5 hold recommendations, and 3 sell recommendations.
Sun Pharmaceutical Industries on Smartkarma
Analysts on Smartkarma are closely covering Sun Pharmaceutical Industries. Tina Banerjee‘s bullish insight titled “Sun Pharmaceutical (SUNP IN): Timely Succession Plan to Augur Well for Next-Level of Growth” highlights the appointment of Kirti Ganorkar as MD, signaling a positive outlook. The company’s India business and specialty segment are gaining momentum, positioning Sun Pharma for growth. The succession plan coincides with a pivotal moment for the company.
In a contrasting view, Tina Banerjee‘s bearish report titled “Sun Pharmaceutical (SUNP IN): Checkpoint Acquisition Does Not Check All the Boxes” scrutinizes Sun Pharma’s acquisition strategy, particularly the proposed acquisition of Checkpoint Therapeutics for ~$200M. Despite potential long-term benefits, the analyst cautions that the acquisition may not generate immediate value for Sun Pharma due to historical acquisition challenges. It’s crucial for Sun Pharma to navigate regulatory hurdles and integration to capitalize on the acquisition fully.
A look at Sun Pharmaceutical Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
“`html
Based on the Smartkarma Smart Scores, Sun Pharmaceutical Industries presents a promising long-term outlook. With a strong growth score of 5, the company is set to expand its presence in the pharmaceutical market. Additionally, scoring high on resilience with a 5 rating, Sun Pharmaceutical Industries is well-equipped to weather economic uncertainties and market fluctuations.
Furthermore, the company’s solid dividend score of 4 signifies its commitment to rewarding shareholders. While the momentum score of 3 indicates room for improvement, Sun Pharmaceutical Industries‘ value score of 2 suggests potential opportunities for value investors. Overall, Sun Pharmaceutical Industries, a leading pharmaceutical manufacturer with a diverse portfolio catering to various medical needs, stands out as a resilient and growth-oriented investment option in the long run.
“`
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
